A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
== Example secreted proteins == α-Amylase (1A, 1B, 1C) – breaks down carbohydrates, especially starch. Histatin (HTN1, HTN3) – have a variety of roles from inhibiting fungus growth, acting as precursors for enamel, and promoting wound healing. Lactoperoxidase – reacts with thiocyanate ions to produce antimicrobial molecules. Lactoferrin – binds to iron which has antimicrobial effects. Proline rich proteins Basic (1, 2, 3, 4) Acidic (1, 2) Proline-rich protein 4 (PRR4) – Also produced by lacrimal acinar cells Statherin – helps stabilize saliva and prevent calcium precipitation.
Mala is a numbing and pungent seasoning derived from Sichuan peppercorn and chili. Most commonly, mala is made into a sauce (麻辣醬 málàjiàng) by simmering it in oil and other spices. Characteristic of Sichuan cuisine, particularly Chongqing cuisine, it has become one of the most popular and synthesized ingredients in Chinese cuisine.
== Cause == Risk factors for allergies can be placed in two broad categories: host and environmental factors. Host factors include heredity, sex, race, and age, with heredity being by far the most significant. However, there has been a recent increase in the incidence of allergic disorders that cannot be explained by genetic factors alone. Four major environmental candidates are alterations in exposure to infectious diseases during early childhood, environmental pollution, allergen levels, and dietary changes.
PABA is an intermediate in the synthesis of folate by bacteria, plants, and fungi. Many bacteria, including those found in the human intestinal tract such as E. coli, generate PABA from chorismate by the combined action of the enzymes 4-amino-4-deoxychorismate synthase and 4-amino-4-deoxychorismate lyase. Plants produce PABA in their chloroplasts, and store it as a glucose ester (pABA-Glc) in their tissues. The malarial protozoan Plasmodium only make PABA when necessary, preferring to get it from the surroundings if able to. Some bacteria, including a few found in the human microbiome, are unable to make PABA for themselves but can use PABA to make folate. A few are very efficient at the PABA-to-folate conversion despite not making their own PABA. Sulfonamide drugs are structurally similar to PABA, and their antibacterial activity is due to their ability to interfere with the conversion of PABA to folate by the enzyme dihydropteroate synthetase. Thus, bacterial growth is limited through folate deficiency.
Upregulation of receptors is the increase in receptor number or sensitivity of receptors. The receptors involved in functional antagonism are regulated in sensitivity, number and location. Therefore, changes in receptors are common. Using a long-term antagonist drug or continuous exposure to an antagonist may cause the upregulation and hypersensitivity of receptors, which means an increase in the number and sensitivity of receptors. The increase in the number of receptors is due to the increased expression of receptors after prolonged inhibition. The upregulation of receptors is important in the clinical aspect. One example of upregulation of receptors is the upregulation of β-receptors caused by β receptor antagonists (also called β-blocker). The prolonged use of β-blockers results in the blockade of β-receptors, causing cells (mainly myocardial cells) to increase their expression of β-receptor. After removing the blockage, more receptors available for stimulation, resulting in higher sensitivity of β-receptors called the hypersensitivity of β-receptors. Abrupt discontinuation of β-blocker may potentially aggravate coronary artery disease, tachycardia, or even sudden cardiac death. Therefore, to prevent the adverse effects, doses of β-blocker must be reduced gradually over 10–14 days.
Sources: en.wikipedia.org
Commercial nuclear fission reactors are operated in the otherwise self-extinguishing prompt subcritical state. Certain fission products decay over seconds to minutes, producing additional delayed neutrons crucial to sustaining criticality. An example is bromine-87 with a half-life of about a minute. Operating in this delayed critical state, power changes slowly enough to permit human and automatic control. Analogous to fire dampers varying the movement of wood embers towards new fuel, control rods are moved as the nuclear fuel burns up over time. In a nuclear power reactor, the main sources of radioactivity are fission products along with actinides and activation products. Fission products are most of the radioactivity for the first several hundred years, while actinides dominate roughly 103 to 105 years after fuel use. Most fission products are retained near their points of production. They are important to reactor operation not only because some contribute delayed neutrons useful for reactor control, but some are neutron poisons that inhibit the nuclear reaction. Buildup of neutron poisons is a key to how long a given fuel element can be kept in the reactor. Fission product decay also generates heat that continues even after the reactor has been shut down and fission stopped. This decay heat requires removal after shutdown; loss of this cooling damaged the reactors at Three Mile Island and Fukushima. If the fuel cladding around the fuel develops holes, fission products can leak into the primary coolant.
== In diabetes == The fluctuations in the levels of chaperone HSP70 affect the homeostasis. Diabetes leads to several microvasculature and microvasculature diseases like retinopathy, Toll like receptors are integral part of innate immune system and eHSP70 binds to toll like receptors and activates the MyD88 pathway, further stimulating NF-kB, cytokines like TNFα and IL1 β, increased production of reactive oxygen species contributing to insulin resistance and diabetes. Whereas there is decrease in the levels of iHSP70.
Under this new franchise agreement, new owners were disallowed from living more than one hour from their restaurants – restricting them to smaller individuals or ownership groups and preventing large, multi-state corporations from owning franchises. Franchisees were also now prohibited from operating other chains, preventing them from diverting funds away from their Burger King holdings. This new policy effectively limited the size of franchisees and prevented larger franchises from challenging Burger King Corporation as Chart House had. Smith also sought to have BKC be the primary owner of new locations and rent or lease the restaurants to its franchises. This policy would allow the company to take over the operations of failing stores or evict those owners who would not conform to the company guidelines and policies. By 1988, parent company Pillsbury had relaxed many of Smith's changes, scaling back on construction of new locations, which resulted in stalled growth of the brand. Neglect of Burger King by new owner Grand Metropolitan and its successor Diageo further hurt the standing of the brand, causing significant financial damage to BK franchises and straining relations between the parties. By 2001 and after nearly 18 years of stagnant growth, the state of its franchises was beginning to affect the value of the company. One of the franchises most heavily affected by the lack of growth was the nearly 400-store AmeriKing Inc., one of the largest Burger King franchisees.
The molecules that contribute vitamin E activity are four tocopherols and four tocotrienols, within each group of four identified by the prefixes alpha- (α-), beta- (β-), gamma- (γ-), and delta- (δ-). For alpha(α)-tocopherol each of the three "R" sites has a methyl group (CH3) attached. For beta(β)-tocopherol: R1 = methyl group, R2 = H, R3 = methyl group. For gamma(γ)-tocopherol: R1 = H, R2 = methyl group, R3 = methyl group. For delta(δ)-tocopherol: R1 = H, R2 = H, R3 = methyl group. The same configurations exist for the tocotrienols, except that the unsaturated side chain has three carbon-carbon double bonds whereas the tocopherols have a saturated side chain. (Esters such as alpha-tocopherol acetate are digested in the human body to yield the corresponding tocopherol.) Nutritional labeling only takes into account the α-tocopherol form because the human liver preferentially retains this form due to the structure of alpha-tocopherol transfer protein. This form is present in much higher amounts in blood plasma than other forms, and it is known to cover the dietary requirement of vitamin E. The other forms are not considered essential.
Robert John Shiach, Cattleman. For services to the Cattle Industry in Banffshire. William Shiel. For services to Tourism in Northumbria. Trevor Royston Shore, Instructor/Examiner, Dorset County Council Cycle Training Scheme. For services to Road Safety. Joan Silcox. For charitable services in Newcastle-upon-Tyne. Annie Mary Simpson. For services to Education. Sylvia Yvonne Simpson. For services to the Police. Jean Skinner, School Crossing Patrol Warden, Kent County Council. For services to Road Safety. Robert Skinner. For services to the St Andrew's Ambulance Association. David Slater. For services to the community in Worksop Nottinghamshire. Eileen Lorraine Smart, Administrative Assistant, Department of Trade and Industry. Gwenneth Maude Muriel Smewin, lately Headteacher, Dunmore County Infants School, Abingdon, Oxfordshire. For services to Education. Barbara Antoinette Smith, Senior Nurse Manager, Leicester General Hospital. For services to Health Care. Brenda Smith. For charitable services. Carol Beverley Smith, Motor Transport Driver, Ministry of Defence. Graham Arthur Smith, Engineering Manager, Secure Products, Siemens Plessey Systems Ltd. For services to Defence Technology. John McCrindle Smith, . For services to the Magistracy and to the Police Committee in Essex. The Reverend Canon John Reginald Smith. For services to the community in Bury, Greater Manchester. Pauline Smith. For services to the Citizens' Advice Bureau in Sale, Cheshire. Thomas Robert Smith. For services to the community in High Wycombe, Buckinghamshire. Stuart Alan Spears.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.